Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor
Author:
Funder
Amgen Inc.
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s00520-016-3421-x.pdf
Reference41 articles.
1. Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G (2008) Cost of neutropenic complications of chemotherapy. Ann Oncol 19(3):454–460
2. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266
3. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205
4. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916–1924
5. Network NCC: (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Myeloid Growth Factors, Version 2.
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Chemotherapy-induced febrile neutropenia (FN) in the US: healthcare resource utilization (HCRU) and costs;2023-12-07
2. Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy;Journal of the National Comprehensive Cancer Network;2023-09
3. Two decades of pegfilgrastim: what have we learned? Where do we go from here?;Current Medical Research and Opinion;2023-04-08
4. Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study;Journal of Managed Care & Specialty Pharmacy;2023-02
5. Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study;Cancer Control;2023-01-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3